



Our ref: IG/FOI.018.24

30 September 2024

Sent via email to: [REDACTED]

Dear [REDACTED]

Request under the Freedom of Information Act 2000

I write further to your request for information, which was received on 10 September 2024, to confirm, in accordance with S.1(1)(a) of the Freedom of Information Act 2000, that Powys Teaching Health Board (PTHB) does hold the information that you require.

For ease of reference your request is set out below and our response follows:

Your Freedom of Information (FOI) Request:

1. Please can you provide the product names with start and finish dates of all your agreed primary care rebates as of September 2024.
2. I would also like to request the process of how you review and evaluate the rebates presented to you?
3. Please can you also provide a copy of your most up to date primary care rebate policy.

Powys Response:

Q1. Please see the table below for Powys Teaching Health Boards (PTHB) product names with start and finish dates of all your agreed primary care rebates as of September 2024.

Rebate	Company	Start	End
Abtard	Ethypharm UK Ltd	Oct-2015	no end date
Adcal D3	Kyowa Kirin International UK NewCo Ltd	Jan-2016	no end date
Ajovy	Teva UK Ltd	Apr-2023	Mar-2025

Pencadlys
Tŷ Glasbury, Ysbyty Bronllys,
Aberhonddu, Powys LD3 0LU
Ffôn: 01874 711661



Headquarters
Glasbury House, Bronllys Hospital
Brecon, Powys LD3 0LU
Tel: 01874 711661



Alzest	Dr Reddys Laboratories (UK) Ltd	Oct-2022	Sep-2024
Amgevita	Amgen	Oct-2022	Sep-2025
Aproderm	Fontus Health	Oct-2023	Sep-2026
Aquacel	Conva Tec Ltd	Jul-2023	Jun-2024
Balneum	Almirall	Oct-2021	Sep-2024
BD Viva Needles 2	Embecta U.K. Limited	Jan-2024	Mar-2025
Bupeaze	Dr Reddys Laboratories (UK) Ltd	Oct-2022	Sep-2024
Buvidal	Camurus	Oct-2022	Jun-2024
Cetraben 3	Thornton & Ross	Jan-2022	Dec-2024
Clenil Modulite	Chiesi Ltd	Jan-2024	Dec-2025
Codimaz	Scope Ophthalmics Ltd	Jul-2023	Jun-2026
Cosentyx	Novartis Pharmaceuticals Ltd	Apr-2023	Dec-2025
Cynril	Fontus Health	Jan-2024	Dec-2026
Dimaz	Scope Ophthalmics Ltd	Jul-2023	Jun-2026
Edoxaban	Daiichi Sankyo UK Ltd	Jan-2023	Dec-2024
Emeside	Fontus Health	Jan-2024	Dec-2026
Epesri	Strides Pharma UK Ltd	Apr-2022	Mar-2025
Epidyolex	GW Pharma Limited	Oct-2021	Sep-2024
Eplaid	Dr Reddys Laboratories (UK) Ltd	Oct-2022	Sep-2024
Espranor	Ethypharm UK Ltd	Jan-2022	Dec-2024
Evrenzo	Astellas Pharma Europe Ltd	Jan-2023	Dec-2025
Fencino 2	Luye Pharma	Jan-2023	no end date
Firmagon	Ferring	Oct-2019	Dec-2024
Fixkoh - 2	Thornton & Ross	Oct-2021	Mar-2025
Fortisip	Nutricia Advanced Medical Nutrition Ltd	Jan-2024	Dec-2024
Fostair NEXThaler	Chiesi Ltd	Jan-2024	Dec-2025
Fostair pMDI	Chiesi Ltd	Apr-2024	Mar-2026
Fycompa	Eisai Limited	Apr-2023	Mar-2026
Glucophage SR	Merck Serono Limited	Jan-2022	no end date
Hanixol	Fontus Health	Jan-2020	Dec-2024

Hylo Fresh	Scope Ophthalmics Ltd	Apr-2022	Mar-2025
Hylo Ointment Night	Scope Ophthalmics Ltd	Apr-2022	Mar-2025
Idacio	Fresenius Kabi Limited	Jul-2023	Jun-2024
Jyseleca	Galapagos Biotech Ltd	Jan-2024	Dec-2026
Leqvio	Novartis Pharmaceuticals Ltd	Jan-2022	Dec-2024
Lumecare	Medicom Healthcare Ltd	Jan-2020	Jun-2024
Luventa	Fontus Health	Oct-2015	no end date
Mircera	Roche Diabetes Care Limited	Oct-2023	Sep-2025
Neorecormon	Roche Diabetes Care Limited	Oct-2023	Sep-2025
NILEMDO & NUSTENDI	Daiichi Sankyo UK Ltd	Apr-2021	Mar-2031
Olumiant	Eli Lilly and Company Limited	Jul-2018	Sep-2025
Omnitrope SurePal	Sandoz	Jul-2021	Jun-2024
Orobalin	Northumbria Pharma Ltd	Jan-2021	Dec-2024
Otezla	Amgen	Jan-2023	Dec-2025
Physeptone	Ethypharm UK Ltd	Oct-2021	Sep-2024
Pipexus	Ethypharm UK Ltd	Jul-2018	no end date
Praluent	Aventis Pharma Limited T/A Sanofi	Oct-2022	Dec-2024
Prostap DCS	Takeda	Apr-2017	no end date
Ranexa	A.Menarini Farmaceutica Internazionale SRL	Oct-2022	Sep-2024
Repatha	Amgen	Jul-2016	no end date
Resource Thicken Up Clear	Nestle UK Ltd	Jan-2021	Jun-2024
Revolade	Novartis Pharmaceuticals Ltd	Jan-2022	Dec-2024
Rinvoq	AbbVie Limited	Oct-2023	Sep-2025
Saxenda	Novo Nordisk	Jan-2021	no end date
Sirdupla	Viatrix UK Healthcare Limited	Apr-2024	Mar-2025
Slenyto	Flynn Pharma	Apr-2021	Mar-2027
Sprycel (Dasatinib)	Bristol-Myers Pharmaceuticals Limited Squibb	Jul-2018	no end date

Strivit-D3	Strides Pharma UK Ltd	Jul-2023	Mar-2025
Tasigna	Novartis Pharmaceuticals Ltd	Jul-2022	Dec-2024
Teraleve	Dr Reddys Laboratories (UK) Ltd	Apr-2022	Mar-2025
Tolthen XL	Northumbria Pharma Ltd	Oct-2021	Sep-2024
Tolthen XL	Fontus Health	Jan-2024	Dec-2026
Viscotears	Bausch & Lomb UK Ltd	Jul-2023	Jun-2025
Vizidor	Bausch & Lomb UK Ltd	Jul-2023	Jun-2025
Vliwasorb Pro	Lohmann & Rauscher	Jul-2022	Jun-2024
WaveSense JAZZ	AgaMatrix Europe Ltd	Apr-2021	Jun-2024
Wegovy FlexTouch	Novo Nordisk	Oct-2023	no end date
Xaggitin	Ethypharm UK Ltd	Apr-2017	no end date
Xailin	Visufarma	Jul-2022	Jun-2024
Xarelto	Bayer	Oct-2020	no end date
Xolair	Novartis Pharmaceuticals Ltd	Apr-2023	Dec-2025
Xtandi	Astellas Pharma Europe Ltd	Oct-2021	Sep-2025
Zaluron XL	Fontus Health	Oct-2015	no end date
Zaponex	Leyden Delta	Jul-2023	Jun-2026

Q2. I can confirm rebates are managed and presented via the CDQ Solutions Ltd rebate platform. Negotiated rebates are reviewed and evaluated on a quarterly basis by the Primary Care Medicines Management team before implementation is considered.

Q3. I can confirm rebates are negotiated at a national level; PTHB does not have a primary care rebate policy.

Under the terms of the Health Board's Freedom of Information procedure, individuals seeking access to recorded information held by the Health Board are entitled to request an internal review of the handling of their requests. If you would like to complain about the Health Board's handling of your request, please contact us directly at the address below or register your complaint via powysfoi.foi@wales.nhs.uk

If after Internal Review you remain dissatisfied you are also entitled to refer the matter to the information commissioner at the Information Commissioner's Office (Wales), 2nd Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH. Telephone Number: 0330 414 6421.

Yours sincerely



Richard Stratton
Assistant Medical Director: Primary Care and Community; Service Development

Rydym yn croesawu derbyn gohebiaeth yng Nghymraeg. Byddwn yn ateb y fath ohebiaeth yng Nghymraeg ac ni fydd hyn yn arwain at oedi.

We welcome receiving correspondence in Welsh. We will reply to such correspondence in Welsh and this will not lead to a delay.